nach oben

CardioVascular and Interventional Radiology

Erschienen in:

02.01.2019 | Clinical Investigation

Radioembolization with ⁹⁰Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity

verfasst von: A. J. A. T. Braat, S. C. Kappadath, H. Ahmadzadehfar, C. L. Stothers, A. Frilling, C. M. Deroose, P. Flamen, D. B. Brown, D. Y. Sze, A. Mahvash, M. G. E. H. Lam

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Radioembolization of liver metastases of neuroendocrine neoplasms (NEN) has shown promising results; however, the current literature is of limited quality. A large international, multicentre retrospective study was designed to address several shortcomings of the current literature.

Materials

244 NEN patients with different NEN grades were included.

Methods

Primary outcome parameters were radiologic response 3 and 6 months after treatment according to RECIST 1.1 and mRECIST. Secondary outcome parameters included clinical response, clinical and biochemical toxicities.

Results

Radioembolization resulted in CR in 2%, PR in 14%, SD in 75% and PD 9% according to RECIST 1.1 and in CR in 8%, PR in 35%, SD in 48% and PD in 9% according to mRECIST. Objective response rates improved over time in 20% and 26% according to RECIST 1.1. and mRECIST, respectively. Most common new grade 3–4 biochemical toxicity was lymphocytopenia (6.7%). No unexpected clinical toxicities occurred. Radioembolization-specific complications occurred in < 4%. In symptomatic patients, improvement and resolution of symptoms occurred in 44% and 34%, respectively. Median overall survival from first radioembolization was 3.7, 2.7 and 0.7 years for G1, G2 and G3, respectively. Objective response is independent of NEN grade or primary tumour origin. Significant prognostic factors for survival were NEN grade/Ki67 index, ≥ 75% intrahepatic tumour load, the presence of extrahepatic disease and disease control rate according to RECIST 1.1.

Conclusion

Safety and efficacy of radioembolization in NEN patients was confirmed with a high disease control rate of 91% in progressive patients and alleviation of NEN-related symptoms in 79% of symptomatic patients.

Level of evidence

Nur mit Berechtigung zugänglich

Heetfeld M, Chougnet CN, Olsen IH, et al. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22(4):657–64. https://doi.org/10.1530/ERC-15-0119.CrossRefPubMed

Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endcr Pathol. 2014;25(2):186–92. https://doi.org/10.1007/s12022-014-9313-z.CrossRef

Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76. https://doi.org/10.1159/000335597.CrossRefPubMed

Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18. https://doi.org/10.1016/j.ecl.2010.12.005.CrossRefPubMed

Frilling A, Li J, Malamutmann E, Schmid KW, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96(2):175–84. https://doi.org/10.1002/bjs.6468.CrossRefPubMed

Strosberg JR, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Eng J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRef

Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–77. https://doi.org/10.1016/S0140-6736(15)00817-X.CrossRefPubMed

Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Eng J Med. 2014;371(3):224–33. https://doi.org/10.1056/NEJMoa1316158.CrossRef

Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Eng J Med. 2011;364(6):501–13. https://doi.org/10.1056/NEJMoa1003825.CrossRef

10.

Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21. https://doi.org/10.1016/S1470-2045(13)70362-0.CrossRefPubMed

11.

Devcic Z, Rosenberg J, Braat AJAT, et al. The efficacy of hepatic ⁹⁰Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med. 2014;55(9):1404–10. https://doi.org/10.2967/jnumed.113.135855.CrossRefPubMed

12.

Kennedy AS, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HBP (Oxford). 2015;17(1):29–37. https://doi.org/10.1111/hpb.12326.CrossRef

13.

Lam MGEHLJ, Iagaru AH, Goris ML, Sze DY. Safety of repeated yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2013;36(5):1320–8. https://doi.org/10.1007/s00270-013-0547-9.CrossRefPubMed

14.

Salem R, Lewandowski RJ, Gates VL, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22(3):265–78. https://doi.org/10.1016/j.jvir.2010.10.029.CrossRefPubMedPubMedCentral

15.

Response Evaluation Criteria In Solid Tumors. www.recist.com. Accessed March 2016.

16.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.CrossRefPubMed

17.

USA NCI. Common terminology criteria in adverse events, version 4.03 (CTCAE v4.03). NIH. 2010. http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf. Accessed March 2016.

18.

Ludwig JM, Ambinder EM, Ghodadra 3, et al. Lung shunt fraction prior to yttrium-90 radioembolization predicts survival in patients with neuroendocrine liver metastases: single-center prospective analysis. Cardiovasc Intervent Radiol. 2016;39(7):1007–14. https://doi.org/10.1007/s00270-016-1323-4.

19.

Sommer WH, Ceelen F, Garcia-Albeniz X, et al. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013;23(11):3094–103. https://doi.org/10.1007/s00330-013-2925-8.CrossRefPubMed

20.

Peker A, Çiçek O, Soydal Ç, et al. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol. 2015;21(1):54–9. https://doi.org/10.5152/dir.2014.14036.CrossRefPubMed

21.

Singla S, LeVea CM, Pokuri VK, et al. Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. J Gastrointest Oncol. 2016;7(3):441–8. https://doi.org/10.21037/jgo.2016.02.02.CrossRefPubMedPubMedCentral

22.

Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97(4):537–43. https://doi.org/10.1002/bjs.6931.CrossRefPubMed

23.

Chen JX, Rose S, White SB, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40(1):69–80. https://doi.org/10.1007/s00270-016-1478-z.CrossRefPubMed

24.

Barbier CE, Garske-Román U, Sandström M, et al. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging. 2016;43(8):1425–31. https://doi.org/10.1007/s00259-015-3264-6.CrossRefPubMed

25.

Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271–9. https://doi.org/10.1097/COC.0b013e31815e4557.CrossRefPubMed

26.

Saxena A, Chua TC, Bester L, et al. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251(5):910–6. https://doi.org/10.1097/SLA.0b013e3181d3d24a.CrossRefPubMed

27.

Ozao-Choy J, Friedman ML, Kim AS, et al. Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers. Pancreas. 2013;42(2):358–60. https://doi.org/10.1097/MPA.0b013e31825f4087.CrossRefPubMed

28.

Tomozawa Y, Jahangiri Y, Pathak P, Kolbeck KJ, Schenning RC, Kaufman JA, Farsad K. Long-term toxicity after transarterial radioembolization with yttrium-90 using resin microspheres for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2018;29(6):858–65. https://doi.org/10.1016/j.jvir.2018.02.002.CrossRefPubMed

29.

Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74(5):1494–500. https://doi.org/10.1016/j.ijrobp.2008.10.005.CrossRefPubMed

30.

Elschot M, Nijsen JF, Lam MGEH, et al. (⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres. Eur J Nucl Med Mol Imaging. 2014;41(10):1965–75. https://doi.org/10.1007/s00259-014-2784-9.CrossRefPubMed

31.

Soulen MC, van Houten D, Teitelbaum UR, Damjanov N, Cengel KA, Metz DC. Safety and feasibility of integrating yttrium-90 radioembolization with capecitabine-temozolomide for grade 2 liver-dominant metastatic neuroendocrine tumors. Pancreas. 2018;47(8):980–4.CrossRefPubMed

32.

Braat AJAT, Kwekkeboom DJ, Kam BLR, et al. Additional hepatic ¹⁶⁶Ho-radioembolization in patients with neuroendocrine tumours treated with ¹⁷⁷Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). BMC Gastroenterol. 2018;18(1):84. https://doi.org/10.1186/s12876-018-0817-8.CrossRefPubMedPubMedCentral

33.

Mikell JK, Mahvash A, Siman W, et al. Selective internal radiation therapy with yttrium-90 glass microspheres: biases and uncertainties in absorbed dose calculations between clinical dosimetry models. Int J Radiat Oncol Biol Phys. 2016;96(4):888–96. https://doi.org/10.1016/j.ijrobp.2016.07.021.CrossRefPubMedPubMedCentral

34.

Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68. https://doi.org/10.1007/s00259-013-2395-x.CrossRefPubMedPubMedCentral

35.

Smits MLJ, Elschot M, Sze DY, et al. Radioembolization dosimetry: the road ahead. Cardiovasc Intervent Radiol. 2015;38(2):261–9. https://doi.org/10.1007/s00270-014-1042-7.CrossRefPubMed

36.

Chansanti O, Jahangiri Y, Matsui Y, et al. tumor dose response in yttrium-90 resin microsphere embolization for neuroendocrine liver metastases: a tumor-specific analysis with dose estimation using SPECT-CT. J Vasc Interv Radiol. 2017;28(11):1528–35. https://doi.org/10.1016/j.jvir.2017.07.008.CrossRefPubMed

37.

Fidelman N, Kerlan RK Jr, Hawkins RA, et al. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014;45(2):168–80. https://doi.org/10.1007/s12029-013-9566-7.CrossRefPubMed

38.

Turkmen C, Ucar A, Poyanli A, et al. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm. 2013;28(7):534–40. https://doi.org/10.1089/cbr.2012.1455.CrossRefPubMed

39.

Cramer B, Xing M, Kim HS. prospective longitudinal quality of life assessment in patients with neuroendocrine tumor liver metastases treated with 90Y radioembolization. Clin Nucl Med. 2016;41(12):e493–7. https://doi.org/10.1097/RLU.0000000000001383.CrossRefPubMed

Titel: Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity
verfasst von: A. J. A. T. Braat
S. C. Kappadath
H. Ahmadzadehfar
C. L. Stothers
A. Frilling
C. M. Deroose
P. Flamen
D. B. Brown
D. Y. Sze
A. Mahvash
M. G. E. H. Lam
Publikationsdatum: 02.01.2019
Verlag: Springer US
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 3/2019
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-018-2148-0

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Radioembolization with ⁹⁰Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity